PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 281 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,531,576 | +391.7% | 49,921 | +542.2% | 0.00% | – |
| Q2 2023 | $311,504 | +377.7% | 7,774 | -99.5% | 0.00% | -100.0% |
| Q1 2023 | $65,212 | +46.6% | 1,597,943 | +38.7% | 0.04% | +48.0% |
| Q4 2022 | $44,469 | -99.8% | 1,151,754 | +146.1% | 0.02% | +66.7% |
| Q3 2022 | $24,897,000 | +1261.2% | 468,074 | +1391.9% | 0.02% | +1400.0% |
| Q2 2022 | $1,829,000 | -77.1% | 31,375 | -76.3% | 0.00% | -75.0% |
| Q4 2021 | $7,972,000 | +106.9% | 132,483 | +92.5% | 0.00% | +100.0% |
| Q3 2021 | $3,854,000 | -57.0% | 68,822 | -53.4% | 0.00% | -60.0% |
| Q2 2021 | $8,956,000 | +11.8% | 147,587 | +29.1% | 0.01% | -16.7% |
| Q1 2021 | $8,014,000 | +55.8% | 114,340 | +33.0% | 0.01% | +50.0% |
| Q4 2020 | $5,145,000 | +1.9% | 85,984 | +2.4% | 0.00% | -33.3% |
| Q3 2020 | $5,049,000 | +2351.0% | 83,989 | +2037.1% | 0.01% | – |
| Q2 2020 | $206,000 | -96.4% | 3,930 | -97.7% | 0.00% | -100.0% |
| Q1 2020 | $5,648,000 | -56.5% | 168,454 | -41.2% | 0.01% | -18.8% |
| Q4 2019 | $12,987,000 | -46.6% | 286,680 | -55.1% | 0.02% | -57.9% |
| Q3 2019 | $24,332,000 | -62.3% | 639,139 | -56.9% | 0.04% | -60.8% |
| Q2 2019 | $64,528,000 | +55.0% | 1,483,737 | +35.7% | 0.10% | +56.5% |
| Q1 2019 | $41,626,000 | -21.0% | 1,093,703 | -10.7% | 0.06% | -24.4% |
| Q4 2018 | $52,679,000 | -25.0% | 1,224,514 | -14.3% | 0.08% | -4.7% |
| Q3 2018 | $70,234,000 | +108.2% | 1,428,970 | +35.8% | 0.09% | +95.5% |
| Q2 2018 | $33,733,000 | +21.9% | 1,052,503 | +18.5% | 0.04% | +18.9% |
| Q1 2018 | $27,673,000 | +12.3% | 888,391 | +64.6% | 0.04% | +8.8% |
| Q4 2017 | $24,644,000 | -44.5% | 539,849 | -42.0% | 0.03% | -57.5% |
| Q2 2017 | $44,412,000 | +609.2% | 931,065 | +578.0% | 0.08% | +627.3% |
| Q1 2017 | $6,262,000 | -81.6% | 137,323 | -87.0% | 0.01% | -84.5% |
| Q4 2016 | $34,017,000 | +513.9% | 1,053,151 | +550.4% | 0.07% | +688.9% |
| Q3 2016 | $5,541,000 | -80.2% | 161,915 | -80.5% | 0.01% | -85.9% |
| Q2 2016 | $28,051,000 | +19.4% | 831,606 | +87.6% | 0.06% | +8.5% |
| Q1 2016 | $23,491,000 | -27.4% | 443,400 | +5.2% | 0.06% | -13.2% |
| Q4 2015 | $32,358,000 | +54.0% | 421,386 | -17.6% | 0.07% | +65.9% |
| Q3 2015 | $21,006,000 | -48.4% | 511,099 | -11.2% | 0.04% | -46.8% |
| Q2 2015 | $40,705,000 | +473.3% | 575,570 | +620.3% | 0.08% | +492.3% |
| Q1 2015 | $7,100,000 | -52.7% | 79,909 | -52.8% | 0.01% | -59.4% |
| Q4 2014 | $15,008,000 | +88.9% | 169,274 | +106.4% | 0.03% | +60.0% |
| Q3 2014 | $7,947,000 | -74.6% | 81,999 | -76.0% | 0.02% | -77.0% |
| Q2 2014 | $31,341,000 | +39.8% | 341,177 | +6.5% | 0.09% | +33.8% |
| Q1 2014 | $22,420,000 | +429.6% | 320,334 | +335.1% | 0.06% | +400.0% |
| Q4 2013 | $4,233,000 | -77.8% | 73,626 | -81.5% | 0.01% | -78.7% |
| Q3 2013 | $19,092,000 | +13.6% | 397,132 | -31.5% | 0.06% | +17.3% |
| Q2 2013 | $16,802,000 | – | 579,390 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |